Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Impact of age on immune checkpoint blockade tolerability across malignancies: A single institution review.

Sub-category:
Immune Checkpoint Inhibitors

Category:
Developmental Therapeutics—Immunotherapy

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e15069

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e15069)

Author(s): Sharon Li, Reetu Mukherji, Sheel A. Patel, Daniel S. Altman, Philip Margiotta, Mario Caldararo, Sean Clark-Garvey, Thomas Holden, Marlana M. Orloff, Ryan Michael Weight, Jennifer Maria Johnson; Jefferson Medcl Coll, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Thomas Jefferson University, Philadelphia, PA, US; Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA; Thomas Jefferson University, Department of Medical Oncology, Philadelphia, PA

Abstract Disclosures

Abstract:

Background: Immune checkpoint inhibitors have become an integral part of treatment for a variety of malignancies. Given the favorable side effect profile compared to chemotherapy, there is increased interest in using immunotherapy in senior adults. Unfortunately, there is limited and conflicting data exploring the effect of age on checkpoint blockade efficacy and toxicity. We hypothesize that due to increased immune-senescence, older patients will experience less treatment limiting immune toxicity. Methods: A total of 170 patients were identified as receiving anti CTLA-4 or -1/PDL-1 antibodies between 2012 and 2017 at TJUH. Data was analyzed by age cohorts: age < 65, age 65-74, and age > 75. Chi-square analysis was used to compare the various reasons for therapy discontinuation between age groups. Results: 47% of patients were less than age 65; 37% were between age 65 and 75 and 16% of patients were older than age 75. Baseline characteristics between the groups were similar. Median CCI and RMH score was similar across the groups. Interestingly, the rate of immune toxicity requiring therapy discontinuation was higher among patients > 75 compared to < 65 though not significantly different (p = .098). Conversely, rates of disease progression while on immunotherapy were significantly higher in patients < 65 compared to those > 75 years (p = value here 0.037). Conclusions: Despite evidence for immuno-senescence in the elderly, rates of immune toxicity did not differ significantly by age. Further studies are needed to explore interplay of aging, the immune system and check point inhibitors.

Reasons for Discontinuing Checkpoint Blockade, n (%)

Age Group (yrs)< 6565-75> 75
Number of Patients80 (47.1)63 (37.0)27 (15.9)
Number of disease sites; mean (median)2.91 (3)2.82 (3)3.08 (3)
Charleston Comorbidity Index at Immunotherapy Initiation;
mean (median)
0.76 (1)0.80 (1)1.41 (1)
Royal Marsden Score at Immunotherapy Initiation;
mean (median)
7.22 (8)8.85 (9)8.22 (9)
Doses of Immunotherapy;
mean (median)
7.6 (4)7.6 (4)8.7 (4.5)
Disease progression Rate32 (40.0)33 (52.4)6 (22.2)
Immunotoxicity Rate10 (12.5)13 (20.6)7 (25.9)
Death Rate9 (11.3)6 (9.5)4 (18.5)
Never discontinued treatment21 (26.3)6 (9.5)5 (18.5)

 
Other Abstracts in this Sub-Category:

 

1. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

Meeting: 2018 ASCO Annual Meeting Abstract No: 3000 First Author: Timothy Anthony Yap
Category: Developmental Therapeutics—Immunotherapy - Immune Checkpoint Inhibitors

 

2. Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.

Meeting: 2018 ASCO Annual Meeting Abstract No: 3001 First Author: Rachel E. Sanborn
Category: Developmental Therapeutics—Immunotherapy - Immune Checkpoint Inhibitors

 

3. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

Meeting: 2018 ASCO Annual Meeting Abstract No: 3006 First Author: Adi Diab
Category: Developmental Therapeutics—Immunotherapy - Immune Checkpoint Inhibitors

 

More...